DelveInsight launched a new report on Acute Respiratory Distress Syndrome Market Insights, Epidemiology and Market Forecast 2030.
Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication in ARDS is that fluid leaks into the lungs, making breathing difficult or impossible. Acute lung injury (ALI) is a common condition characterized by acute severe hypoxia that is not due to left atrial hypertension.
DelveInsight’s ‘Acute Respiratory Distress Syndrome (ARDS) Market Report 2030’ delivers an in-depth understanding of the Acute Respiratory Distress Syndrome (ARDS), historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome (ARDS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The term ALI encompasses a continuum of clinical and radiographic changes that affect the lungs with the acute respiratory distress syndrome (ARDS) representing the more severe end of this continuum. Despite advances in the understanding of the pathophysiology and management of ALI, it is still associated with high mortality.
“In the 7MM, the total incident population of ARDS is estimated to be 7,99,872 in 2017.”
Acute Respiratory Distress Syndrome Emerging Drug Therapies:
1. Traumakine: Faron Pharmaceuticals
2. BIO-11006: BioMarck Pharmaceuticals
3. MultiStem: Athersys
4. Solnatide: Apeptico Forschung und Entwicklung GmbH
“The market size of Acute Respiratory Distress Syndrome (ARDS) in the seven major markets is USD 3,007.1 Million in 2017.”
Table of contents: 1 Key Insight 2 Executive Summary of ARDS 3 Acute Respiratory Distress Syndrome (ARDS) Market Overview at a Glance 4 Disease Background and Overview: ARDS 5 Case Reports 6 Acute Respiratory Distress Syndrome (ARDS)Epidemiology and Patient Population 7 United States Epidemiology 8 EU5 Epidemiology 9 Japan Epidemiology 10 Current Acute Respiratory Distress Syndrome (ARDS) Treatment and Medical Practices 11 Unmet needs 12 Acute Respiratory Distress Syndrome (ARDS) Marketed Drugs 13 Acute Respiratory Distress Syndrome (ARDS) Emerging Drugs 14 Acute Respiratory Distress Syndrome (ARDS) 7MM Market Analysis 15 United States 16 EU-5 countries: Market Outlook 17 Japan Market Outlook 18 Acute Respiratory Distress Syndrome (ARDS) Market Drivers 19 Acute Respiratory Distress Syndrome (ARDS) Market Barriers 20 SWOT Analysis 21 Reimbursement and market access 22 Appendix 23 DelveInsight Capabilities 24 Disclaimer 25 About DelveInsight
View report: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/